Pfizer Presents Positive Data From Phase 2 Study of Ponsegromab in Patients With Cancer Cachexia
Pfizer Presents Positive Data From Phase 2 Study of Ponsegromab in Patients With Cancer Cachexia
辉瑞公司发布了Ponsegromab在癌症恶病质患者中的2期研究积极数据
- Study met primary endpoint of change from baseline in body weight for ponsegromab compared to placebo across all ponsegromab doses tested, reaching 5.6% mean increase at the highest dose evaluated at 12 weeks; ponsegromab was generally considered safe and well-tolerated at all dose levelsi
- At the highest dose evaluated, improvements were seen from baseline in appetite and cachexia symptoms, physical activity, and muscle massi
- Based on positive Phase 2 results, registration-enabling studies will start in 2025
- 在全部试验剂量中，ponsegromab相对安慰剂在体重改变的一级终点达到了研究的主要终点，在12周时达到了最高剂量下5.6%的平均增加；ponsegromab在所有剂量水平下普遍被认为是安全的、耐受良好的。
- 在最高剂量评估时，相对于基线，食欲和消瘦症状、身体活动和肌肉质量均有改善。
- 基于积极的2期结果，可用于登记的研究将于2025年开始。